Primary viral infectious disease
MONDO:0100329The initial viral infectious disase that causes illness.
3708 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Sanofi's COVID vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis Phase 3 study tested two Sanofi COVID-19 vaccines (one targeting the original virus, another targeting two variants) in about 24,000 adults. The goal was to see if they could prevent COVID-19 safely. The trial was terminated early, so final results are limited, but the data …
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
MRNA shingles vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis study tested several experimental mRNA vaccines against shingles in healthy adults aged 50 to 85. The goal was to check safety and immune response compared to the current shingles vaccine, Shingrix. The trial was terminated early, so results are limited, but the data may hel…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Experimental HIV vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tested an experimental HIV vaccine in 44 healthy adults to see if it was safe and triggered an immune response. The vaccine uses a piece of the HIV virus (fusion peptide) to train the body's defenses. The study was terminated early, so the full results are …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
Ebola vaccine in a nasal spray? early trial halted
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tested a nasal spray vaccine against Ebola in 15 healthy adults. The vaccine uses a weakened common cold virus to deliver a piece of the Ebola virus. The study aimed to check safety and immune response, but it was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:03 UTC
-
New RSV vaccine for infants shows promise in major trial
⭐️ VACCINE ⭐️ TerminatedThis study tested an experimental RSV vaccine given to healthy infants at 6 and 12 months old alongside their regular vaccines. The goal was to see if the RSV vaccine still worked well when given at the same time. About 2,200 babies took part, but the study was stopped early.
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
Could a Lower-Dose RSV vaccine protect babies just as well?
⭐️ VACCINE ⭐️ TerminatedThis study tested a nasal spray RSV vaccine in nearly 1,000 healthy infants and toddlers aged 6 to 22 months. The goal was to see if a lower dose works as well as the standard dose and to check safety across different doses. The trial was ended early, so final results are not ava…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
RSV nasal vaccine trial for kids halted – what we know
⭐️ VACCINE ⭐️ TerminatedThis phase 3 study tested an intranasal RSV vaccine in about 6,300 healthy children aged 6 to 22 months. The goal was to see if two doses of the nasal spray could prevent lower respiratory tract infections caused by RSV. The trial was terminated early, so final results are not av…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
UK volunteers test new ebola vaccine combo in Early-Stage trial
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tested the safety and immune response of two experimental Ebola vaccines in 38 healthy UK adults. Some volunteers received one vaccine, while others got a prime-boost combination. The vaccines use harmless viruses to train the immune system against Ebola wi…
Phase: PHASE1 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:05 UTC
-
New mRNA vaccine aimed at preventing common but risky virus
⭐️ VACCINE ⭐️ TerminatedThis phase 3 trial tested an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in healthy people aged 16 to 40. The study enrolled over 7,400 participants, focusing on women who had never been infected with CMV. The vaccine aims to trigger an immune response to …
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:04 UTC
-
COVID vaccine trial for babies halted early – Here's what we know
⭐️ VACCINE ⭐️ TerminatedThis study looked at whether the mRNA-1273.214 COVID-19 vaccine is safe and works in infants as young as 12 weeks to under 6 months old. It was a small, early-stage trial that was stopped before completion. The main goal was to check for side effects like fever, fussiness, and in…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:00 UTC
-
Sanofi mRNA vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis study tested Sanofi's experimental mRNA vaccine against COVID-19 in 182 healthy adults aged 18 and older. The main goals were to check safety and measure the body's immune response. The trial was terminated early, so full results are not available.
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 15:56 UTC
-
Could a simple pill tame RSV? new trial tests obeldesivir
Disease control TerminatedThis phase 2 study tests whether an oral antiviral pill called obeldesivir can safely shorten RSV symptoms in adults who are not hospitalized but are at higher risk for severe disease (e.g., those aged 60+ or with chronic lung conditions). Participants take the pill or a placebo,…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Malaria drug combo shows promise against COVID-19 in early trial
Disease control TerminatedThis phase 2 trial tests whether a combination of atovaquone (an anti-malarial) and azithromycin (an antibiotic) can clear the COVID-19 virus in infected adults. The study enrolls people at high risk for complications, such as those with moderate to severe illness. Participants r…
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Peer support may boost HIV treatment success in people who inject drugs
Disease control TerminatedThis study tests whether adding peer-based counseling to standard HIV and opioid treatment helps people who inject drugs stay on their medications and achieve viral suppression. Participants receive either enhanced usual care or extra support from a peer counselor. The goal is to…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Placenta cells tested as COVID fighter – but trial stopped early
Disease control TerminatedThis early-phase trial tested a new therapy called CYNK-001, which uses natural killer cells from the placenta to fight COVID-19. It enrolled only 7 adults with moderate COVID-19. The study was terminated early, so we have limited information on safety and effectiveness.
Phase: PHASE1, PHASE2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental drug aims to help COVID survivors breathe easier
Disease control TerminatedThis study tested a drug called deupirfenidone (LYT-100) in 185 adults who had breathing problems after a serious COVID-19 infection. Participants took either the drug or a placebo for several weeks to see if it improved their ability to walk. The trial was stopped early, so the …
Phase: PHASE2 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Mpox drug trial halted: did tecovirimat help?
Disease control TerminatedThis study tested whether the drug tecovirimat could safely treat mpox and speed up recovery. About 719 people with mpox took either tecovirimat or a placebo. The main goals were to see if the drug reduced the time for skin lesions to heal and lessened pain. The study was termina…
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New oral pill aims to fight RSV in adults
Disease control TerminatedThis study tests an oral drug called AK0529 (Ziresovir) in adults aged 18 to 75 with respiratory syncytial virus (RSV) infection. Participants receive either the drug or a placebo, and researchers measure how well symptoms improve and track any side effects. The goal is to see if…
Phase: PHASE2 • Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Liver transplants for HIV-HCV patients: a feasibility study
Disease control TerminatedThis study aimed to see if liver transplantation is possible and safe for people infected with both HIV and hepatitis C. Fifteen patients were enrolled to track survival, virus behavior, and drug interactions after transplant. The goal was to understand how these two viruses inte…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hepatitis b drug combo trial halted early
Disease control TerminatedThis early-stage study tested a new experimental drug called GSK3965193, alone and in combination with another drug (bepirovirsen), for people with chronic hepatitis B. The goal was to see if the combination could lower hepatitis B virus levels and possibly lead to a sustained re…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control TerminatedThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
COVID-19 drug trial halted early: only 16 patients enrolled
Disease control TerminatedThis study tested an experimental drug called APX-115 in hospitalized patients with mild to moderate COVID-19. The goal was to see if it was safe and could help people recover faster. However, the trial was stopped early and only 16 people took part, so we don't have enough infor…
Phase: PHASE2 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a smaller dose of arthritis drug tame COVID-19 lung inflammation?
Disease control TerminatedThis study tested whether a low dose of tocilizumab, a drug used for arthritis, could help hospitalized COVID-19 patients with lung inflammation who were not on a breathing machine. The goal was to see if it sped up recovery and reduced deaths. The trial was stopped early, but re…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
HIV drug showdown: which strategy works best for new patients?
Disease control TerminatedThis study compared two HIV treatment approaches in people who had never taken HIV drugs before. One group started with a three-drug combo for 16 weeks, then switched to a two-drug combo. The other group took a two-drug combo from the start. The goal was to see if the first appro…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
HIV drug switch may boost heart health and trim body fat
Disease control TerminatedThis study looked at whether switching from a standard HIV drug combination to a different one (Delstrigo) could improve cholesterol, body fat, and blood sugar in people with HIV. The study planned to enroll 60 adults whose HIV was already well-controlled. Participants were rando…
Phase: PHASE4 • Sponsor: Chelsea and Westminster NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Hospital hep c treatment aims to cure drug users
Disease control TerminatedThis study tested giving hepatitis C treatment to people who inject drugs while they were already in the hospital for other infections. The goal was to cure their hepatitis C and make sure they stayed connected to care afterward. The study was stopped early, but it included 21 pa…
Phase: NA • Sponsor: Kirby Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental immune cell therapy for transplant viruses shows early promise but study halted
Disease control TerminatedThis early-stage trial tested whether specially grown immune cells could help transplant patients fight off stubborn viral infections. The study included 8 people who had received a stem cell or organ transplant and had ongoing infections with adenovirus, CMV, or EBV. The approac…
Phase: PHASE1, PHASE2 • Sponsor: Jessie L. Alexander, MD • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental drug INB03 tested to stop COVID-19 lung decline – trial halted early
Disease control TerminatedThis study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could prevent their breathing from getting worse. Participants received two weekly injections of either INB03 or a placebo. The trial was terminated early, so we do not have clear results on whet…
Phase: PHASE2, PHASE3 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Plasma from recovered patients tested against COVID-19 – trial ends early
Disease control TerminatedThis study tested whether giving plasma (the liquid part of blood) from people who recovered from COVID-19 could help hospitalized patients with moderate to severe COVID-19. The plasma contains antibodies that might fight the virus. The trial planned to enroll many patients but w…
Phase: PHASE3 • Sponsor: South African National Blood Service • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Heart drug tested to fight COVID-19 complications
Disease control TerminatedThis study tested a drug called CardiolRx in 90 hospitalized COVID-19 patients who also had heart disease or risk factors like diabetes or high blood pressure. The goal was to see if the drug could lower the chance of death, needing intensive care, or having heart problems. The t…
Phase: PHASE2, PHASE3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Weekly HIV pill shows promise but study halted early
Disease control TerminatedThis study tested whether a once-weekly oral combination of two experimental drugs (lepetegravir and lenacapavir pacfosacil) could control HIV as well as the standard daily pill Biktarvy. It enrolled 73 people newly diagnosed with HIV-1 who had never taken HIV medication. The stu…
Phase: PHASE2, PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Hormone therapy and HIV drugs: a delicate balance for transgender women
Disease control TerminatedThis study looked at how feminizing hormone therapy (estradiol) interacts with HIV medications in transgender women living with HIV. It included 93 participants who were already on HIV treatment and gave them standardized estradiol doses for up to 48 weeks. The goal was to see if…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
HIV and opioid treatment study halted early – what we know
Disease control TerminatedThis study looked at whether different medications for opioid use disorder (methadone, buprenorphine/naloxone, or naltrexone) could reduce immune system inflammation in people with HIV. Researchers measured changes in blood markers of immune activation over 24 weeks. The trial wa…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Hepatitis b drug combo tested in phase 3 trial – but study stopped early
Disease control TerminatedThis study tested two antiviral drugs, clevudine and tenofovir, alone or together, in 150 adults with chronic hepatitis B who had not been treated before. The goal was to see which approach worked best at controlling the virus after 96 weeks of treatment and 24 weeks of follow-up…
Phase: PHASE3 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
HIV pill combo fails to slim belly fat in early trial
Disease control TerminatedThis study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Cancer drug tested against COVID-19 in small trial
Disease control TerminatedThis study tested whether imatinib, a drug used for certain cancers, could help hospitalized adults with COVID-19. Participants received either imatinib or a placebo alongside standard care. The trial was stopped early and only included 21 people, so no firm conclusions can be dr…
Phase: PHASE3 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple gas stop COVID-19 from getting worse?
Disease control TerminatedThis study tested whether breathing in nitric oxide gas could keep mild-to-moderate COVID-19 from becoming severe. Researchers enrolled 62 hospitalized adults who were breathing on their own. The goal was to see if the gas reduced the need for a breathing tube. The trial was stop…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental drug auxora tested in critical COVID-19 lung patients
Disease control TerminatedThis small Phase 2 trial tested an experimental drug called Auxora in 10 patients with critical COVID-19 pneumonia who were on ventilators. The goal was to see how the drug affected immune cells in the lungs and to check its safety. The study was terminated early, so results are …
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental donor CAR-T therapy tested in lymphoma – trial halted early
Disease control TerminatedThis early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped ea…
Phase: PHASE1 • Sponsor: Atara Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a nausea drug help fight COVID-19? early trial cut short
Disease control TerminatedThis phase 2 trial tested whether adding aprepitant, a drug usually used for nausea, to standard care could help hospitalized COVID-19 patients recover faster. The study planned to enroll adults recently admitted to the hospital with COVID-19 and signs of lung involvement. Howeve…
Phase: PHASE2 • Sponsor: Heron Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
Disease control TerminatedThis early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…
Phase: PHASE1, PHASE2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug fails to show benefit in severe COVID-19 pneumonia trial
Disease control TerminatedThis study tested whether adding reparixin to standard care could prevent death or the need for a breathing machine in 414 hospitalized adults with COVID-19 or other pneumonia. The trial was stopped early. Researchers compared reparixin to a placebo to see if it reduced severe ou…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New vaccine aims to tame hepatitis b in patients on antivirals
Disease control TerminatedThis study tested a new therapeutic vaccine (GSK3528869A) in adults aged 18-65 with chronic hepatitis B whose virus was already well-controlled by standard antiviral pills. The goal was to see if the vaccine could safely lower hepatitis B surface antigen levels and possibly allow…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can texts and peers help trans women beat HIV? trial cut short
Disease control TerminatedThis study aimed to find the best way to help transgender women living with HIV reach undetectable viral levels. Participants received either text messages, help from a peer health navigator, or both. The trial was ended early, so results are limited.
Phase: NA • Sponsor: Friends Research Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can an arthritis drug tame severe COVID-19?
Disease control TerminatedThis study tested the drug tocilizumab (Actemra) in hospitalized adults with severe COVID-19 and signs of inflammation. Participants received either the drug or a placebo, with the goal of improving clinical status by day 28. The trial was terminated early after enrolling only 20…
Phase: PHASE3 • Sponsor: Queen's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Hydroxychloroquine COVID trial fizzles: only 17 patients enrolled
Disease control TerminatedThis study tested whether hydroxychloroquine (a malaria drug) could help hospitalized COVID-19 patients recover faster. It planned to enroll 350 people but was stopped early with just 17 participants. Because it ended so early, we cannot say whether the drug works or is safe for …
Phase: PHASE3 • Sponsor: Queen's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
COVID-19 drug trial halted early: what happened with ensovibep?
Disease control TerminatedThis study tested a single dose of ensovibep, a lab-made protein, in 407 adults with mild COVID-19 symptoms. The goal was to see if it could lower the amount of virus in the body and reduce hospitalizations. The trial was stopped early, so we don't have complete answers on how we…
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
COVID-19 drug trial halted after just 4 patients
Disease control TerminatedThis study tested whether a medicine called emetine could help adults aged 30 and older recover from COVID-19. Participants took emetine or a placebo daily for 10 days. The trial was stopped early after only 4 people enrolled, so we don't have enough information to know if emetin…
Phase: PHASE2, PHASE3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hepatitis b drug trial halted after early safety check
Disease control TerminatedThis early-stage study tested a new medicine called RO7565020 in healthy volunteers and people with chronic hepatitis B. The goal was to see if the drug is safe and how the body processes it. The trial was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
HIV cancer hope: immune combo shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested two immunotherapy drugs, ipilimumab and nivolumab, in people with HIV who had advanced solid tumors or Hodgkin lymphoma that had spread or come back. The goal was to find the safest dose and see if the combination could shrink tumors. The study was t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis Phase 2 trial tested an experimental drug called ARC-520 in 58 people with chronic hepatitis B who were already taking standard antivirals. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels, a marker of the virus. The study was terminated …
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis study tested a new drug called ARC-520 in 79 people with chronic hepatitis B. Some participants received ARC-520 alone, while others got it combined with standard treatments like entecavir or tenofovir. The goal was to see if ARC-520 could lower hepatitis B surface antigen l…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Hepatitis b drug trial halted early after safety check
Disease control TerminatedThis early-stage study tested an experimental drug called ARC-521 in healthy volunteers and people with chronic hepatitis B. The main goal was to check safety and how the body processes the drug. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug combo shows promise but study halted early
Disease control TerminatedThis study tested an experimental drug called ARC-520 given alongside standard hepatitis B medications (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks to see if it could safely lower hepatitis B virus levels. …
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis study tested whether a new drug called ARC-520, given with the standard medicine entecavir, could lower hepatitis B virus levels in people with chronic hepatitis B. About 58 adults with different stages of infection received either ARC-520 or a placebo. The study was stopped…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called ARC-520 in 32 adults with chronic hepatitis B who were already taking antiviral medications (entecavir or tenofovir). The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more than placebo. The trial wa…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Cancer Patients' COVID-19 trial halted after just 4 volunteers
Disease control TerminatedThis early-phase study aimed to see if combining two immune-stimulating drugs (rintatolimod and interferon alpha-2b) could help cancer patients fight off COVID-19. Only 4 people took part before the study was stopped early. The main goals were to check safety and measure how the …
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental drug aims to keep viral pneumonia patients out of hospital
Disease control TerminatedThis Phase 2 trial tested the drug silmitasertib (CX-4945) plus standard care in adults with pneumonia caused by COVID-19 or influenza. The goal was to see if the drug could reduce the need for hospitalization or prevent death. The study planned to enroll 120 people but was termi…
Phase: PHASE2 • Sponsor: Senhwa Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New RSV drug tested in kids – but trial halted early
Disease control TerminatedThis study tested the safety and dosing of sisunatovir, an experimental antiviral drug, in infants and children up to 5 years old with RSV lower respiratory tract infection. Ten participants received either the drug or a placebo. The goal was to find the right dose for future stu…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
COVID drug trial for kids halted early
Disease control TerminatedThis study tested the drug baricitinib in children aged 1 to 18 who were hospitalized with COVID-19 and needed extra oxygen. The goal was to see if the drug was safe and how it worked in kids. Only 6 children took part before the study was stopped early.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can an antiviral drug help sepsis patients breathe on their own sooner?
Disease control TerminatedThis phase 3 trial tested whether the antiviral drug ganciclovir could prevent reactivation of cytomegalovirus (CMV) in adults with sepsis who needed a breathing machine. The study enrolled 205 CMV-positive patients in the ICU with acute respiratory failure. Participants received…
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
HepTcell hepatitis b vaccine trial ends early: what it means
Disease control TerminatedThis study tested a treatment called HepTcell, which is like a vaccine that trains the immune system to fight the hepatitis B virus. It was for people with inactive chronic hepatitis B who had not received treatment before. The goal was to see if it could lower virus levels or cl…
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Polio Survivors' hope dashed: trial of immune treatment halted early
Disease control TerminatedThis study tested a blood product called immune globulin (Flebogamma) in 191 people with post-polio syndrome, a condition causing new muscle weakness years after polio. The goal was to see if it could improve walking distance and reduce pain. The trial was terminated early, so we…
Phase: PHASE2, PHASE3 • Sponsor: Instituto Grifols, S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Experimental COVID-19 drug fails to prevent respiratory failure in High-Risk patients
Disease control TerminatedThis study tested an experimental drug called ABX464 in 509 high-risk COVID-19 patients aged 65 and older, or those 18+ with risk factors like obesity or diabetes. The goal was to see if the drug could reduce inflammation and prevent the need for high-flow oxygen or a breathing m…
Phase: PHASE2, PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
COVID pill trial halted early: what happened?
Disease control TerminatedThis study tested an oral antiviral drug called ensitrelvir in hospitalized COVID-19 patients. The goal was to see if it could help them recover faster. However, the trial was stopped early, so we have limited information on whether it works.
Phase: PHASE3 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental HIV therapy aims to free patients from daily pills
Disease control TerminatedThis early-stage trial tests two experimental vaccines, HB-502 and HB-501, designed to teach the immune system to recognize and attack HIV. The study includes 30 people with HIV who are already on suppressive antiretroviral therapy. Participants receive injections every 8 weeks f…
Phase: PHASE1 • Sponsor: Hookipa Biotech GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
COVID-19 drug trial halted: LAU-7b studied in hospitalized patients
Disease control TerminatedThis study tested an experimental drug called LAU-7b in adults hospitalized with COVID-19 who had health issues like diabetes that put them at higher risk for complications. The goal was to see if LAU-7b could prevent respiratory failure or the need for a breathing machine. The t…
Phase: PHASE2, PHASE3 • Sponsor: Laurent Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
HIV drug extension study halted early: what happened?
Disease control TerminatedThis study looked at whether weekly injections of PRO 140, taken with standard HIV medications, could keep the virus under control over the long term. It enrolled 43 people who had already completed an earlier PRO 140 study and had undetectable virus levels. The study was termina…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
RSV pill study halted early: what we know
Disease control TerminatedThis study tested an oral drug called sisunatovir for treating RSV in adults who were not hospitalized but had a high risk of severe illness. Participants took either the drug or a placebo for 5 days. The study was terminated early, so results are limited.
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising combo for tough blood cancers halted early — only 4 patients enrolled
Disease control TerminatedThis study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early…
Phase: PHASE1, PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental hepatitis b drug trial halted early
Disease control TerminatedThis study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels. Only 4 people enrolled before the study was stop…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
HIV patients test weekly shots to replace daily pills
Disease control TerminatedThis study tested whether HIV patients who already had the virus under control could switch to weekly injections of leronlimab (PRO 140) instead of their usual daily pills. The goal was to see if the drug alone could keep the virus suppressed safely over a longer period. The tria…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
COVID-19 antibody drug trial halted early — little data to show
Disease control TerminatedThis early-stage study tested a new antibody drug (REGN14256) alone or with imdevimab in 25 adults with mild COVID-19 and no risk factors for severe illness. The goal was to check safety and whether the drug could lower virus levels. However, the trial was terminated early, so we…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control TerminatedThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can a drug combo let HIV patients ditch daily meds?
Disease control TerminatedThis study tested two experimental drugs, budigalimab and ABBV-382, in people with HIV who were stable on standard therapy. Participants stopped their usual HIV medications to see if the new drugs could keep the virus under control. The trial was terminated early, so it's unclear…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
COVID antibody drug trial halted: hope for severe cases unfulfilled
Disease control TerminatedThis study tested a lab-made antibody called SCTA01 in adults hospitalized with severe COVID-19. The goal was to see if it could help them recover faster. The trial was stopped early, so we don't have clear results on its effectiveness.
Phase: PHASE2, PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New HIV drug candidate GS-1219 tested in tiny early trial
Disease control TerminatedThis was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New program aims to boost HIV medication adherence for medicaid patients
Disease control TerminatedThis study tested a program to help Virginia Medicaid enrollees with HIV fill their antiretroviral prescriptions on time. The program offered support from providers, pharmacies, and community groups, with extra help for those who were very late refilling. Only 4 people enrolled b…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New HIV drug trial halted early – what happened?
Disease control TerminatedThis study tested an experimental HIV drug called VH3739937 in 21 adults with HIV who had never taken HIV medication before. The goal was to see how well the drug lowered the virus level in the blood over a short time. The trial was stopped early, and results are limited.
Phase: PHASE2 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
COVID antibody study for vulnerable kids halted early
Disease control TerminatedThis study tested a single injection of two lab-made antibodies (casirivimab and imdevimab) in children under 12 who are at high risk for severe COVID-19. The goal was to see how the drug behaves in the body, if it is safe, and if it triggers an immune response. Only 7 children t…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
COVID antibody drug tested in kids – but study stopped early
Disease control TerminatedThis study tested a single dose of casirivimab+imdevimab (REGN-COV2) in children hospitalized with COVID-19. The goal was to see how the drug behaves in the body and whether it is safe. However, the study was terminated early and only enrolled 2 participants, so we have very litt…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
HIV Antibody-Only therapy falls short in Long-Term trial
Disease control TerminatedThis study tested whether a single antibody called PRO 140 could keep HIV under control in 20 adults who had been stable on standard combination therapy. Participants stopped their usual HIV pills and received only PRO 140 infusions. The trial was stopped early, and the main goal…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody treatment aims to shield transplant patients from dangerous virus
Disease control TerminatedThis study tested a drug called Cytotect, which contains antibodies against the CMV virus, to prevent CMV infection in people who had a stem cell transplant and developed graft-versus-host disease (GVHD). These patients are at high risk for CMV, and current antiviral drugs often …
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Stem cell infusions aim to tame COVID-19 inflammation
Disease control TerminatedThis study tested whether infusions of stem cells from donated fat tissue could help people with COVID-19. The trial planned to enroll 48 adults and compare four doses of stem cells against a placebo. The goal was to see if the treatment could reduce inflammation and improve oxyg…
Phase: PHASE2 • Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Hydroxychloroquine trial for COVID-19 fizzles out
Disease control TerminatedThis early-phase study tested whether hydroxychloroquine, a drug used for malaria and autoimmune diseases, could reduce the amount of virus in adults with mild COVID-19 not needing oxygen. Only 8 people took part before the trial was stopped early. The study was too small to draw…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope against deadly molds? early trial cut short
Disease control TerminatedThis study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.
Phase: PHASE2 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
Kidney transplant patients get extra COVID shot in new trial
Disease control TerminatedThis phase 3 trial tested whether a dose of the Janssen COVID-19 vaccine could boost immunity in kidney transplant recipients who had already received two or three mRNA vaccine doses. The study enrolled 468 participants and also looked at reducing immunosuppression medication. Ho…
Phase: PHASE3 • Sponsor: Mark Stegall • Aim: Disease control
Last updated Jun 26, 2026 17:26 UTC
-
Nasal spray aims to fight COVID-19, but trial halted early
Disease control TerminatedThis study tested a nasal spray called AD17002 in 180 adults with mild to moderate COVID-19. Participants received either a low dose, high dose, or placebo spray alongside standard care. The goal was to see if the spray speeds up recovery and improves symptoms. However, the trial…
Phase: PHASE2, PHASE3 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC
-
Stem cell shot for COVID-19 fizzles in small trial
Disease control TerminatedThis study tested whether a single infusion of stem cells from umbilical cord tissue (ProTrans®) could help hospitalized adults with severe COVID-19 avoid ventilators or death. The trial was stopped early after enrolling only 19 people, so we cannot draw firm conclusions. Both th…
Phase: PHASE2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
Hepatitis b cure hope fades as early trial ends
Disease control TerminatedThis small phase 2 trial tested whether giving hepatitis B antibodies (HBIG) could clear the hepatitis B surface antigen in people with chronic hepatitis B. Only 13 patients were enrolled before the study was terminated. The goal was to see if a 12-week course of injections could…
Phase: PHASE2 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Jun 26, 2026 13:38 UTC
-
Fatty liver drug trial in HIV patients stalls after enrolling just 4 people
Disease control TerminatedThis study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaning…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC
-
Rapid COVID test studied for emergency triage
Diagnosis TerminatedThis study looked at using a fast, point-of-care COVID-19 test to help doctors quickly decide how to treat patients with serious heart or breathing problems. It involved 66 adults who already tested positive for COVID-19. The goal was to find the best way to collect samples (nose…
Sponsor: Ottawa Heart Institute Research Corporation • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Fingerprint sweat may reveal COVID-19 infection
Diagnosis TerminatedThis study explored whether analyzing sweat from fingerprints using a special camera could quickly detect COVID-19. Researchers enrolled 66 adults who had tested positive or negative for COVID-19 within the past week. Participants provided a fingerprint sweat sample and a blood s…
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 12:25 UTC
-
Can a One-Minute chair test predict COVID-19 hospital needs?
Diagnosis TerminatedThis study tested whether a one-minute sit-to-stand test could help emergency doctors decide if COVID-19 patients need hospital care. The test measures oxygen levels and breathing effort during repeated standing from a chair. The trial aimed to reduce unnecessary hospital stays b…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Monthly HIV prevention pill trial halted Mid-Study
Prevention TerminatedThis study tested a once-monthly pill called islatravir to prevent HIV infection in cisgender men and transgender women who have sex with men and are at high risk. About 494 participants were enrolled, but the trial was terminated early. The main goal was to check safety and see …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
ERs could be key to boosting HPV shots in High-Risk adults
Prevention TerminatedThis study explored whether giving the HPV vaccine in the emergency department (ER) could help protect adults aged 18-45 who haven't been fully vaccinated. Researchers enrolled 34 participants and offered the vaccine during their ER visit, with follow-up doses at 2 and 6 months. …
Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jun 27, 2026 12:09 UTC
-
Phone app aims to boost HIV testing in young black men and transwomen
Prevention TerminatedThis study tested a mobile-friendly tool that helps young Black men and transwomen who have sex with men or transwomen pick the best HIV testing method for them, such as self-testing or clinic testing. The goal was to see if this personalized recommendation could increase how oft…
Phase: NA • Sponsor: New York Blood Center • Aim: Prevention
Last updated Jun 27, 2026 12:05 UTC
-
Could a simple gas shield healthcare workers from COVID-19?
Prevention TerminatedThis study tested whether breathing in nitric oxide gas could prevent healthcare workers from catching COVID-19. The plan was to enroll 470 workers, but the trial was stopped early with only 24 participants. Workers in the treatment group inhaled the gas at the start and end of e…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 11:04 UTC
-
Wolbachia-Infected mosquitoes released to fight dengue, zika, and chikungunya
Prevention TerminatedThis trial tested a method to control mosquito-borne diseases like dengue, Zika, and chikungunya by releasing male Aedes aegypti mosquitoes infected with Wolbachia bacteria. These males mate with wild females, causing their eggs to die, which reduces the mosquito population. The …
Phase: NA • Sponsor: Michigan State University • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
New approach aims to boost HIV prevention in LGBTQ+ individuals struggling with addiction
Prevention TerminatedThis study tested a program to help HIV-negative transgender women and men who have sex with men who also have a substance use disorder stick with PrEP, a daily pill or shot that prevents HIV. Participants received counseling and text support, with extra help for those who strugg…
Phase: NA • Sponsor: Friends Research Institute, Inc. • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Monthly HIV prevention pill tested in women – study halted early
Prevention TerminatedThis study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so results are limited. The goal was to offer a more convenient prevention option.
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
Super-Sized flu shot for tots? study tests higher dose
Prevention TerminatedThis study tested whether a high-dose flu vaccine works better than the standard dose in preventing the flu in children aged 6 to 35 months. About 100 children took part, receiving either the high-dose or standard-dose shot. The study was stopped early, so results are limited.
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
Antibody shield for the vulnerable: COVID-19 prevention trial in immunocompromised
Prevention TerminatedThis study tested whether a combination of antibodies (casirivimab+imdevimab) could prevent COVID-19 in people with weakened immune systems, such as transplant recipients or cancer patients. Participants received either the antibodies or a placebo as a shot under the skin. The tr…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC
-
Nasal spray could be new weapon against COVID-19
Prevention TerminatedThis study tested whether a nitric oxide nasal spray could prevent COVID-19 in people at risk of exposure. About 1,400 adults used the spray or a placebo for 28 days. The trial was terminated early, so final results are not available.
Phase: PHASE3 • Sponsor: Sanotize Research and Development corp. • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
Super-Sized flu shot tested for Seniors' heart and lung protection
Prevention TerminatedThis study compared a high-dose flu vaccine to the standard-dose shot in over 33,000 adults aged 65 and older. The goal was to see if the high-dose version could better prevent hospitalizations for heart and lung problems. The trial was terminated early, so the full picture is no…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 17:31 UTC
-
Mental health sessions may boost vaccine uptake in latinx communities
Prevention TerminatedThis study tested whether adding vaccine discussions to routine behavioral health visits could reduce hesitancy and increase COVID-19 and flu shots among Latinx adults with mental illness. Clinicians used motivational interviewing and could offer a warm handoff to a nurse for vac…
Phase: NA • Sponsor: Boston College • Aim: Prevention
Last updated Jun 26, 2026 17:00 UTC
-
HIV drug fails to prove COVID-19 prevention in abandoned trial
Prevention TerminatedThis study tested whether a daily pill used for HIV (TAF/FTC) could prevent COVID-19 in healthcare workers at high risk of exposure. Over 1,300 workers were randomly assigned to get the drug or a placebo for 12 weeks. The trial was stopped early, so it's unclear if the drug had a…
Phase: PHASE3 • Sponsor: Hospital Italiano de Buenos Aires • Aim: Prevention
Last updated Jun 26, 2026 14:58 UTC
-
Egg-Free flu vaccine tested in kids: could it be just as good?
Prevention TerminatedThis study compared a newer recombinant flu vaccine (RIV4, also called Supemtek or Flublok Quadrivalent) to the standard egg-based flu vaccine in 366 children aged 3 to 8 years. The goal was to see if the recombinant vaccine produced a similar immune response and was as safe. The…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 14:42 UTC
-
RSV drug trial for kids under 5 halted early – only 4 children enrolled
Symptom relief TerminatedThis study tested an oral antiviral drug called obeldesivir in children from birth to under 5 years old who had RSV infection. The goal was to see if the drug is safe and helps reduce symptoms faster. However, the trial was stopped early and only enrolled 4 participants, so the r…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Youth HIV study tests talking circles for better mental health
Symptom relief TerminatedThis study tested whether a group therapy program, led by trained youth leaders, could improve mental health and help young people with HIV stick to their medication. About 484 youth in low-resource settings took part. The program used trauma-informed counseling adapted to local …
Phase: NA • Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Mindfulness app for anxiety in underserved groups fizzles out early
Symptom relief TerminatedThis study tested a smartphone app that teaches mindfulness meditation to help Black and Latino adults with anxiety during the COVID-19 pandemic. About 400 participants were assigned to one of two mindfulness programs or a waitlist. The trial was terminated early, so we don't hav…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
HIV-Positive Men's mental health study shuts down after just one participant
Symptom relief TerminatedThis study aimed to see if acceptance and commitment therapy (ACT), a type of talk therapy, could help HIV-positive men with mental health issues like stress and anxiety. Only one person enrolled before the study was stopped early. Because of this, no meaningful results were obta…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Salt water gargle study for COVID-19 fizzles out early
Symptom relief TerminatedThis study tested whether rinsing the nose and gargling with salt water could help people with suspected or confirmed COVID-19 feel better faster. Only 16 adults in the UK took part before the study was stopped early. The goal was to see if this simple home remedy could reduce ho…
Phase: NA • Sponsor: University of Edinburgh • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
CBD shows promise for emotional health in HIV patients
Symptom relief TerminatedThis study tested whether synthetic cannabidiol (CBD) could help people living with HIV who have a condition called alexithymia, which makes it hard to recognize and describe emotions. Participants took either CBD or a placebo for 4 weeks. The goal was to see if CBD could improve…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Ancient herbal remedy put to the test against COVID-19
Symptom relief TerminatedThis small pilot study tested whether a traditional Chinese medicine called Xuanfei Baidu granules is safe and acceptable for people with mild to moderate COVID-19. Only 10 adults were enrolled before the study was stopped early. The main goal was to see how many people would agr…
Phase: PHASE2 • Sponsor: Darcy Spicer • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Calm app tested on stressed doctors – but study cut short
Symptom relief TerminatedThis study looked at whether using the Calm meditation app could help medical residents and fellows at Banner University Medical Center Phoenix feel less stressed, anxious, or burned out during the COVID-19 pandemic. Only 7 people signed up, and the study was stopped early, so we…
Phase: NA • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Long COVID rehab study halted early – what we know
Symptom relief TerminatedThis study looked at whether a supervised exercise and pulmonary rehabilitation program could help people with Long COVID feel better and move more easily. Researchers measured changes in aerobic capacity, fatigue, and quality of life in 21 adults who had COVID at least 12 weeks …
Phase: NA • Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
HIV patients may age faster: study probes skin, muscle, and bone health
Knowledge-focused TerminatedThis study compared signs of aging in 123 HIV-infected adults to the general population. Researchers measured bone density, muscle strength, skin changes, and thinking abilities. The goal was to understand if HIV speeds up aging in these areas. No new treatment was tested; it was…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
COVID-19 vaccine safety checked in cancer immunotherapy patients
Knowledge-focused TerminatedThis study aimed to see if COVID-19 vaccines cause more side effects in cancer patients receiving immunotherapy. Researchers planned to track 125 patients from several hospitals in France, recording any local or systemic side effects. The study was terminated early, so the full r…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Could a common virus trigger thyroid troubles?
Knowledge-focused TerminatedThis study investigated whether polyomaviruses (a type of common virus) are found more often in people with autoimmune thyroiditis or goiters. Researchers compared virus presence in blood, urine, and thyroid tissue from 49 patients undergoing thyroid surgery. The goal was to see …
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists collect samples from COVID-19 patients to unlock virus secrets
Knowledge-focused TerminatedThis study collected blood, urine, stool, and respiratory samples from 615 COVID-19 patients and caregivers at Bordeaux University Hospital. The goal was to build a biobank for research on the virus and disease. The study was terminated early, but the samples may still help scien…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
COVID-19 may harm the brain in ways scans Can't see
Knowledge-focused TerminatedThis study looked for hidden brain damage in 38 hospitalized COVID-19 patients. Instead of using standard MRI scans, researchers used electrical tests to check how well the brainstem was working. The goal was to find subtle nervous system problems that might not show up on regula…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Web tool aims to ease tough COVID conversations
Knowledge-focused TerminatedThis study tested a web-based guide to help people have conversations about COVID-19. It enrolled 30 adults who spoke English or Spanish. The guide offered virtual conversations tailored to different concerns. The study was terminated early, so results are limited.
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Scientists investigate mpox in severely weakened immune systems
Knowledge-focused TerminatedThis study looked at how the mpox virus spreads and how the immune system responds in people with advanced HIV. Researchers tracked the virus in different body samples and measured immune markers to better understand severe illness. The goal is to use these findings to improve tr…
Sponsor: Centers for Disease Control and Prevention • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New ICU cockpit software aims to predict brain complications before they happen
Knowledge-focused TerminatedThis study tested a software platform called ICU Cockpit that collects and displays vital signs and other data from brain-injury patients in the intensive care unit. The goal was to help doctors make faster, better decisions and to predict complications like strokes or unstable c…
Phase: NA • Sponsor: Emanuela Keller • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
AI analyzes 100,000 COVID-19 cases to predict who gets worst outcomes
Knowledge-focused TerminatedThis study used artificial intelligence to analyze electronic health records from 100,000 COVID-19 patients across multiple hospitals. The goal was to identify factors that predict whether a patient would be hospitalized, need ICU care, or die. The study was terminated early, so …
Sponsor: Savana Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Web tool aims to boost HIV testing among black women in the south
Knowledge-focused TerminatedThis study tested a web-based program to help Black women in Texas use HIV and STI home tests and connect to treatment or PrEP. The program included five sessions with goal-setting and action plans. Only 31 women enrolled before the study was stopped early, so the findings are li…
Phase: NA • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Rouen hospital checks accuracy of COVID-19 antibody tests
Knowledge-focused TerminatedThis study aimed to check how accurate several COVID-19 antibody tests are. Researchers used blood samples from 101 adults, including some taken before the pandemic and some from people with other infections. The goal was to see which tests best detect past COVID-19 infection.
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Vaccine study aims to unlock secrets of immune memory
Knowledge-focused TerminatedThis study looked at how the hepatitis B vaccine triggers immune cells called B cells to form germinal centers, where antibodies become stronger. Researchers wanted to understand if memory B cells return to these centers after a booster shot. The goal was to learn how to design b…
Phase: PHASE4 • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Smart vest monitors COVID patients
Knowledge-focused TerminatedThis study tested a special vest that tracks health data like heart rate and breathing in people hospitalized with COVID-19. The goal was to see if the vest could help doctors spot worsening symptoms early. Only 15 adults took part before the study ended early.
Sponsor: Nanowear Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Arthritis drugs and COVID: study probes immune response
Knowledge-focused TerminatedThis study looked at how immunosuppressive medications used for rheumatoid arthritis and spondyloarthritis affect the body's ability to fight COVID-19. Researchers measured viral load and immune responses in 150 patients and their infected family members. The goal was to understa…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New brain scanner peers into COVID's neurological mysteries
Knowledge-focused TerminatedThis pilot study tested a new brain PET-MR scanner to see if it can capture clear images of brain metabolism and blood flow in people who had COVID-19 and those who did not. Only 3 participants were enrolled before the study ended early. The goal was to develop an imaging protoco…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Flu vaccine study halted after just 2 volunteers
Knowledge-focused TerminatedThis study aimed to compare how the immune system responds to two different seasonal flu vaccines given at the same time. Healthy adults aged 18-49 who had not received a flu shot in at least three years were eligible. The study was terminated early and only enrolled 2 participan…
Phase: EARLY_PHASE1 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can cheap text messages boost HIV retesting? pilot study seeks answers
Knowledge-focused TerminatedThis pilot study tested several low-cost behavioral nudges, like videos and text messages, to encourage HIV retesting among 98 adults at higher risk of HIV in rural Kenya and Uganda. The goal was to see which approaches were acceptable and feasible, so the best ones could be used…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Sticker shock: simple reminder may cut unnecessary IV antibiotic use
Knowledge-focused TerminatedThis study tested whether placing a reminder sticker on the charts of adult hospital patients receiving IV fluoroquinolone antibiotics would encourage doctors to switch them to oral pills sooner. The trial involved 168 patients at a single hospital in Thailand. Unfortunately, the…
Phase: NA • Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Rural pharmacists get virtual coaching to tackle vaccine hesitancy
Knowledge-focused TerminatedThis study looked at whether virtual coaching helps rural pharmacists better counsel patients who are hesitant about COVID-19 vaccines. Sixteen pharmacies took part, first receiving standard training and then adding one-on-one video coaching. The main goal was to see if coaching …
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
MRI scans aim to uncover hidden ear damage in CMV survivors
Knowledge-focused TerminatedThis study looked at whether people born with cytomegalovirus (CMV) infection who have hearing loss or balance problems also have a condition called endolymphatic hydrops (fluid buildup in the inner ear). Researchers used a special MRI scan with a contrast dye to check for this f…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Hepatitis c blood study halted early: what it means
Knowledge-focused TerminatedThis study aimed to see how often people with chronic hepatitis C have a blood condition called monoclonal B-cell lymphocytosis (MBL), and whether treating hepatitis C affects MBL. Researchers planned to enroll 29 participants and compare blood samples before and after hepatitis …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Cancer Patients' COVID risk explored in terminated study
Knowledge-focused TerminatedThis study aimed to understand how COVID-19 affects people with cancer, especially those receiving treatment. Researchers planned to measure how many cancer patients had COVID-19 without symptoms and how their immune systems responded. The study was terminated early, so results a…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
COVID-19's hidden heart damage: study aims to find clues
Knowledge-focused TerminatedThis study followed 80 adults who recovered from COVID-19 to check for heart problems. Participants had heart exams and blood tests one month and one year after recovery. The goal was to understand how often and what kind of heart issues occur after COVID-19, so doctors can bette…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Updated pfizer Shot's Real-World power under review
Knowledge-focused TerminatedThis study aimed to measure how well the 2024-2025 Pfizer COVID-19 vaccine prevents symptomatic infection in people visiting CVS MinuteClinics. Researchers planned to compare vaccinated and unvaccinated patients across age groups and variant periods. However, the study was termin…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Smart band tracks COVID-19 breathing trouble
Knowledge-focused TerminatedThis study tested a special band called AirGo to monitor breathing patterns in hospitalized COVID-19 patients with respiratory failure. The goal was to see if the band could detect early signs of worsening breathing, helping doctors decide when to use a breathing tube. The study …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Scientists track HPV's secret life in young women
Knowledge-focused TerminatedThis study followed 190 young women to learn how the body handles new HPV infections. Researchers measured virus levels, immune cells, and other factors over time. The goal was to understand why some infections clear quickly while others persist. No treatment was given; this was …
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
HIV study tracks daily movement in NYC
Knowledge-focused TerminatedThis study looked at how much physical activity and sitting time people with HIV in New York City get. Participants wore a small device called an accelerometer for a week to track their movement. The goal was to understand how activity levels relate to overall health. The study w…
Sponsor: Queens College, The City University of New York • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
HIV drugs may weaken bones: new study investigates
Knowledge-focused TerminatedThis study looked at bone density in HIV-positive men to see if antiretroviral drugs cause bone thinning. Researchers compared men starting HIV treatment with those not yet on therapy over two years. The goal was to understand why bone loss is more common in HIV patients.
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Early safety test of iCP-NI drug halted before completion
Knowledge-focused TerminatedThis early-phase study tested the safety and tolerability of an experimental drug called iCP-NI in 24 healthy adults. Participants received either the drug or a placebo by intravenous infusion. The trial was terminated, so no conclusions about effectiveness can be drawn.
Phase: PHASE1 • Sponsor: Cellivery Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:00 UTC
-
Hepatitis b patients under the microscope: new study observes Real-World treatments
Knowledge-focused TerminatedThis study observed over 1,700 adults with chronic hepatitis B in the US and Canada to understand how the disease progresses and how treatments are used in everyday medical practice. Researchers collected data from both academic and community clinics to build a real-world picture…
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:05 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused TerminatedThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
COVID-19's hidden toll on the retina: eye scans reveal damage
Knowledge-focused TerminatedThis study aimed to collect eye scans from people who had COVID-19 to see if the virus caused damage to the retina, the light-sensitive tissue at the back of the eye. Researchers planned to compare severe and mild COVID-19 cases, but the study was stopped early and only enrolled …
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:34 UTC